FDA Signals Faster Drug Approvals for Multiple Myeloma — Positive Read for Legend Biotech

FDA draft guidance supports new approval endpoints in multiple myeloma, potentially speeding drug development and boosting prospects for Legend Biotech’s CARTITUDE-6.